Welcome
Support Centre
02 September 2010 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ Print-friendly version ]
Mini-Allografting to complement treatment with Glivec (Imatinib - formerly known as STI571) to eradicate minimal residual disease (MRD) in Chronic Myeloid Leukaemia (CML) patients aged 65 years and under with matched sibling donors
Source of recordNHS Trusts Clinical Trials Register - 2004 Update
ISRCTNISRCTN86187144
Title of trialMini-Allografting to complement treatment with Glivec (Imatinib - formerly known as STI571) to eradicate minimal residual disease (MRD) in Chronic Myeloid Leukaemia (CML) patients aged 65 years and under with matched sibling donors
NHS TrustLeeds Teaching Hospitals NHS Trust
Serial number at source/NRR Publication IDN0436130285
Local project referenceHM02/1826
Multicentre trialNo
Lead research centreNo
Start date30/11/2002
End date30/09/2005
StatusCompleted
Disease or conditionCancer: Leukaemia
Topic/hypothesis/clinical objectivesTo develop a novel clinical immune-therapeutic strategy for CML patients aged 65 and under, found to have suitable matched sibling allogeneic donors, and following remission induction with Glivec.
Inclusion criteriaPatients with a diagnosis of Chronic Myeloid Leukaemia, attending the Haematology Out-patients' clinic and who fulfill the eligibility criteria will be invited to join the study.
Exclusion criteriaNot provided at time of registration
Indicative number of participantsNot provided at time of registration
Randomised interventions1. Treatment a
2. Treatment b
Primary outcome measuresSurvival and remission status at 6 months and 1 year post transplant.
Secndary outcome measuresNot provided at time of registration
Sources of fundingLeeds Teaching Hospitals NHS Trust
Contact nameDr G M Smith
Contact detailsHaematological Oncology Department
D Floor, Brotherton Wing
Leeds Teaching Hospitals NHS Trust
Great George Street
Leeds
LS1 3EX
United Kingdom

Tel: +44 (0)113 392 5153
Fax: +44 (0)113 392 6349
Email: graeme.smith@leedsth.nhs.uk
Primary MeSH keywordsLEUKEMIA-MYELOID-CHRONIC Q-therapy; BONE-MARROW-TRANSPLANTATION Q-methods; NEOPLASM-RESIDUAL; ST-1571 Q-therapeutic-use; ANTINEOPLASTIC-AGENTS Q-therapeutic-use; REMISSION-INDUCTION
Secondary MeSH keywordsHUMAN; RANDOMIZED-CONTROLLED-TRIAL; CLINICAL-TRIAL; SURVIVAL-ANALYSIS; AGED; TRANSPLANTATION-HOMOLOGOUS
Further information Trial information has been obtained from the March 2003, 2004, 2005, 2006 and 2007 submissions to the National Research Register (NRR) archived as of Dec 2007.
Date refreshed in mRCT Updated 06 February 2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central